Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) vs. Inhibrx Biosciences (NASDAQ:INBX) Financial Analysis

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Inhibrx Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Volatility & Risk

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 4.03, indicating that its share price is 303% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Lakefront Biotherapeutics American Depositary Shares and Inhibrx Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38
Inhibrx Biosciences	1	2	2	1	2.50

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $35.50, indicating a potential upside of 10.42%. Inhibrx Biosciences has a consensus target price of $197.50, indicating a potential upside of 143.59%. Given Inhibrx Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Inhibrx Biosciences is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Insider and Institutional Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and Inhibrx Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.68	$363.05 million	($1.41)	-22.80
Inhibrx Biosciences	$1.30 million	918.08	-$140.05 million	($8.88)	-9.13

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Inhibrx Biosciences. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Inhibrx Biosciences beats Lakefront Biotherapeutics American Depositary Shares on 7 of the 13 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.